This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

On-Demand
DIGITAL WEEK

FOCUSED AND TIMELY INFORMATION DELIVERED DIRECTLY TO YOU

2019 Antibody Engineering & Therapeutics Digital Week Topics

Access the following on-demand webinars by just signing up! Watch at your leisure any time.

Synthetic DNA Technologies Enable Antibody Discovery and Optimization

Utilizing its proprietary DNA writing technology to create oligo pools, genes, and synthetic libraries, Twist Pharma, a division of Twist Bioscience, provides the biotechnology industry with an end-to-end antibody discovery solution.

 This solution includes (1) a panel of high diversity synthetic antibody libraries, (2) a proprietary human anti-GPCR antibody phage display library focused on this validated target class, and (3) a Twist Antibody Optimization (TAO) platform for antibody affinity and developability optimization. 

Aaron K. Sato, Ph.D.
CSO
Twist Bioscience, Biopharma

Oncolytic Vaccines Encoding T Cell Engagers: Tumor-targeted Delivery and Anti-tumor Synergy

Challenges in current cancer immunotherapy include increasing response rates and decreasing toxicity. We have developed tumor-selective oncolytic vectors for delivery of immunomodulators to avoid systemic exposure and mitigate toxicity. Furthermore, vector-mediated oncolysis serves as an in situ tumor vaccine, inducing synergistic anti-tumor immune responses. This talk highlights the versatility of our vector system and avenues for clinical translation. 

Christine E. Engeland, M.D., Ph.D.,
Physician-Scientist, Departments of Medical Oncology and Translational Oncology,
National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ)

Accelerating target-to-lead antibody candidate selection using the Berkeley Lights Beacon Platform

The development of biologics to novel therapeutic targets is hampered by current antibody discovery technologies that are laborious, time-consuming, and generate limited diversity.  Here I will demonstrate how Berkeley Lights’ BeaconTM platform’s automated plasma cell antibody discovery workflow mines the vast immune repertoire to identify B cells producing rare, functional antibodies to difficult therapeutic targets in under 24 hours.  Unlike other single-cell technologies, the Beacon platform enables users to perform multiple functional assays to enable selection of lead candidates against difficult therapeutic targets.  The Beacon platform links phenotype-to-genotype at the single-cell level, thus simplifying downstream sequencing, cloning, and bioinformatics analysis. 

Anupam Singhal, Ph.D.
Senior Manager, Technology Development
Berkeley Lights, Inc.

"Antibodies to Watch” and More: Early- and Late-stage Clinical Development Trends

The “Antibodies to watch” talks and papers focus on antibody therapeutics in late-stage clinical studies, as well as those is regulatory review and recently approved in the US and European Union. These topics will be discussed, along with trends observed in the burgeoning early-stage pipeline. Popular formats and mechanisms of action, as well as popular and obscure targets, for antibody therapeutics that recently entered the clinical pipeline will be included. 

Janice Reichert, Ph.D.
Managing Director, Reichert Biotechnology Consulting
Executive Director, The Antibody Society

The Design, Optimisation and Manufacture of highly potent ADCs 

There is no one solution to the development of antibody drug conjugates and every target brings its own set of challenges to development such as reagent architecture which plays a critical role in the efficacy of an ADC.

This webinar will show how different conjugations technologies can be assessed side by side for efficacy allowing the ability to screen and rank multiple product candidates to optimise your ADC right from the beginning.

We will also look at what considerations you need to make during process development and manufacturing to ensure you get a homogeneous product.

Mark Frigerio
Director of Chemistry
Abzena

         


CONNECT TO NEW IDEAS AND INNOVATIONS THROUGH WEBINARS

2018 Digital Content still available on-demand

On-Demand Webcasts

Tumor Uptake of PEGylated Diabody: Balancing Between Antibody Size and Systemic Clearance

Therapeutic Targeting of Notch 3 Signaling for Cerebral Small Vessel Disease

High Throughput Characterization of Ion Channel Activity Blocking mAbs with Array SPR

DNA-based Antibody Therapy: A Blueprint for Innovation

New Ways to Boost Recombinant Protein and Antibody Yields in Transient Systems

High Resolution Protein and Antibody Modeling with NovaFold and NovaFold Antibody

Antibodies to Watch in 2018 Update

Emerging Technologies for Finding Rare Antibodies

Why Attend a Webinar?

Time and Cost-Efficient

You will save valuable time and money because there is no need to travel and no registration fee.

Focused and Timely Learning

You will receive the latest "hot" and timely data from a leading authority

Convenience

You can participate in a webinar from a location of your choosing – your home, your office, or a client/customer location

Get the latest event updates

Sign up to get the latest event updates and information.